Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Astellas Pharma gets U.S. nod for blood cancer treatment

November 28, 2018 8:31 PM
117 0

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan’s Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

The treatment, Xospata, was approved for patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant.

Read more

Share in social networks:

Comments - 0